• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Stephens initiated coverage on C4 Therapeutics with a new price target

    11/18/24 8:38:35 AM ET
    $CCCC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CCCC alert in real time by email
    Stephens initiated coverage of C4 Therapeutics with a rating of Equal-Weight and set a new price target of $4.00
    Get the next $CCCC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CCCC

    DatePrice TargetRatingAnalyst
    12/19/2024$8.00 → $12.00Equal Weight → Overweight
    Wells Fargo
    11/18/2024$4.00Equal-Weight
    Stephens
    1/29/2024$6.00Underweight → Neutral
    JP Morgan
    12/13/2023$2.00 → $12.00Hold → Buy
    Stifel
    2/24/2023$12.00 → $10.00Underperform → Neutral
    Credit Suisse
    2/24/2023$15.00 → $5.00Neutral → Underweight
    JP Morgan
    11/4/2022$22.00 → $15.00Overweight → Neutral
    JP Morgan
    10/11/2022$6.00Underweight
    Morgan Stanley
    More analyst ratings

    $CCCC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Grogan Donna Roy was granted 9,581 shares, increasing direct ownership by 29% to 42,280 units (SEC Form 4)

      4 - C4 Therapeutics, Inc. (0001662579) (Issuer)

      4/3/25 4:11:53 PM ET
      $CCCC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Anderson Kenneth Carl was granted 7,841 shares, increasing direct ownership by 7% to 127,609 units (SEC Form 4)

      4 - C4 Therapeutics, Inc. (0001662579) (Issuer)

      4/3/25 4:11:41 PM ET
      $CCCC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President & CEO Hirsch Andrew covered exercise/tax liability with 22,217 shares and was granted 223,500 shares, increasing direct ownership by 91% to 423,145 units (SEC Form 4)

      4 - C4 Therapeutics, Inc. (0001662579) (Issuer)

      2/18/25 4:55:35 PM ET
      $CCCC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care